Abeona Therapeutics (NASDAQ:ABEO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Abeona Therapeutics (NASDAQ:ABEO – Get Rating) in a research note published on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Abeona Therapeutics Trading Down 5.9 %

Shares of ABEO stock opened at $2.39 on Thursday. Abeona Therapeutics has a 52-week low of $2.19 and a 52-week high of $9.35. The business’s fifty day moving average is $2.58 and its 200 day moving average is $3.27.

Institutional Investors Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Creative Planning purchased a new stake in shares of Abeona Therapeutics in the fourth quarter worth $62,000. Dimensional Fund Advisors LP bought a new position in Abeona Therapeutics in the third quarter valued at $103,000. Jane Street Group LLC bought a new position in Abeona Therapeutics in the fourth quarter valued at $115,000. Citigroup Inc. bought a new position in Abeona Therapeutics in the first quarter valued at $27,000. Finally, ExodusPoint Capital Management LP bought a new position in Abeona Therapeutics in the fourth quarter valued at $290,000. Hedge funds and other institutional investors own 37.69% of the company’s stock.

Abeona Therapeutics Company Profile

(Get Rating)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.